These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18706430)

  • 1. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors.
    Nukoolkarn V; Lee VS; Malaisree M; Aruksakulwong O; Hannongbua S
    J Theor Biol; 2008 Oct; 254(4):861-7. PubMed ID: 18706430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
    Ahmad B; Batool M; Ain QU; Kim MS; Choi S
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach.
    Bello M
    J Mol Graph Model; 2020 Dec; 101():107762. PubMed ID: 33022569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.
    Simpson KN; Jones WJ; Rajagopalan R; Dietz B
    Clin Drug Investig; 2007; 27(7):443-52. PubMed ID: 17563124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid peptide-based screening on the substrate specificity of severe acute respiratory syndrome (SARS) coronavirus 3C-like protease by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Chu LH; Choy WY; Tsai SN; Rao Z; Ngai SM
    Protein Sci; 2006 Apr; 15(4):699-709. PubMed ID: 16600962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
    Chu CM; Cheng VC; Hung IF; Wong MM; Chan KH; Chan KS; Kao RY; Poon LL; Wong CL; Guan Y; Peiris JS; Yuen KY;
    Thorax; 2004 Mar; 59(3):252-6. PubMed ID: 14985565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
    Kashuba AD; Tierney C; Downey GF; Acosta EP; Vergis EN; Klingman K; Mellors JW; Eshleman SH; Scott TR; Collier AC
    AIDS; 2005 Jan; 19(2):145-52. PubMed ID: 15668539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs.
    Zhang XW; Yap YL
    Bioorg Med Chem; 2004 May; 12(10):2517-21. PubMed ID: 15110833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
    Komatsu TS; Okimoto N; Koyama YM; Hirano Y; Morimoto G; Ohno Y; Taiji M
    Sci Rep; 2020 Oct; 10(1):16986. PubMed ID: 33046764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
    Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of Gly-11 on the dimer interface results in the complete crystallographic dimer dissociation of severe acute respiratory syndrome coronavirus 3C-like protease: crystal structure with molecular dynamics simulations.
    Chen S; Hu T; Zhang J; Chen J; Chen K; Ding J; Jiang H; Shen X
    J Biol Chem; 2008 Jan; 283(1):554-564. PubMed ID: 17977841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.
    Mo H; Lu L; Dekhtyar T; Stewart KD; Sun E; Kempf DJ; Molla A
    Antiviral Res; 2003 Aug; 59(3):173-80. PubMed ID: 12927307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.
    Tsai KC; Chen SY; Liang PH; Lu IL; Mahindroo N; Hsieh HP; Chao YS; Liu L; Liu D; Lien W; Lin TH; Wu SY
    J Med Chem; 2006 Jun; 49(12):3485-95. PubMed ID: 16759091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QM/QM studies for Michael reaction in coronavirus main protease (3CL Pro).
    Taranto AG; Carvalho P; Avery MA
    J Mol Graph Model; 2008 Oct; 27(3):275-85. PubMed ID: 18567519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.